ASC-61 is under clinical development by Ascletis Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASC-61’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASC-61 is under development for the treatment of solid tumors. It is administered through oral route as tablet formulation. The therapeutic candidate is a small molecule and acts by targeting programmed cell death ligand 1 (PD-L1).
Ascletis Pharma overview
Ascletis Pharma is a pharmaceutical company that develops and commercializes novel drugs for unmet medical needs. The company operates as a investigating ASC09 inhibitor to treat HIV type-1 infections; and ASC06, a novel drug for the treatment of liver cancer through RNA interference. It is also advancing products against COVID-19 and fatty liver diseases. Ascletis Pharma utilizes anti-viral and RNAi platform to develop its pipeline products. The company works in partnership with Roche Holding AG; Presidio Networked Solutions LLC; Medivir AB; Janssen Pharmaceutical NV; and Alnylam Pharmaceuticals Inc for developing its products. Ascletis Pharma is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of ASC-61’s drug-specific PTSR and LoA scores, buy the report here.